Luminescence imaging using radionuclides: a potential application in molecular imaging

Park, Jeong Chan; An, Gwang Il; Park, Se-Il; Oh, Jungmin; Kim, Hong Joo; Ha, Yu; Wang, Eun Kyung; Kim, Kyeong Min; Kim, Jung Young; Lee, Jaetae; Welch, Michael J.; Yoo, Jeongsoo

doi:10.1016/j.nucmedbio.2010.09.003

Cited by 49 publications

(31 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Park et al demonstrated specific uptake of 124 I-labeled trastuzumab by a HER2-expressing tumor (Supplemental Fig. 2B) (15). As previously mentioned, Ruggiero et al developed the 89 Zr-labeled monoclonal antibody 89 Zr-DFO-J591 and demonstrated specific tumor uptake using the inherent CR emitted from this novel radiolabeled immunoconjugate (Supplemental Figs.…”

Section: Applications In Biomedical Research In Vivo Tumor Imagingmentioning

confidence: 82%

“…As is known in nuclear physics, radionuclides decay via a variety of modes including a, b 1 , b 2 , electron capture and isomeric transition. b 1 -emitters include 11 C, 13 N, 15 O, 18 F, 64 Cu, 68 Ga, and 124 I; Robertson et al used 13 N and 18 F to demonstrate CLI (9). On the other hand, 3 H, 14 C, 32 P, 89 Sr, 90 Y, 131 I, and 177 Lu emit principally high-energy b 2 , and the decay of these emitters is often accompanied by g-rays.…”

Section: Recent Advances In Cerenkov Luminescence Imaging (Cli)mentioning

confidence: 99%

“…They also used a radiolabeled prostate-specific membrane antigen targeting the monoclonal antibody 89 Zrdesferrioxamine B [DFO]-J591 for immuno-PET in LNCaP tumor-bearing mice positive for prostate-specific membrane antigen, and the data correlated well both qualitatively and quantitatively with CLI. As another example, Park et al injected 124 I-labeled trastuzumab (Herceptin; Genetech) into HER2-expressing NIH3T6.7 tumor-bearing mice and obtained OI and PET images, both of which showed good signals from tumors (15).…”

Section: Cross Validations Of CLI Petmentioning

confidence: 99%

See 2 more Smart Citations

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Xu¹,

Liu²,

Cheng³

2011

J Nucl Med

129

178

View full text Add to dashboard Cite

Over the past several years, nuclear imaging modalities such as PET and SPECT have received much attention because they have been instrumental not only in preclinical cancer research but also in nuclear medicine. Yet nuclear imaging is limited by high instrumentation cost and subsequently low availability to basic researchers. Cerenkov radiation, a relativistic physical phenomenon that was discovered 70 years ago, has recently become an intriguing subject of study in molecular imaging because of its potential in augmenting nuclear imaging, particularly in preclinical small-animal studies. The intrinsic capability of radionuclides emitting luminescent light from decay is promising because of the possibility of bridging nuclear imaging with optical imaging-a modality that is much less expensive, is easier to use, and has higher throughput than its nuclear counterpart. Thus, with the maturation of this novel imaging technology using Cerenkov radiation, which is termed Cerenkov luminescence imaging, it is foreseeable that advances in both nuclear imaging and preclinical research involving radioisotopes will be significantly accelerated in the near future.

show abstract

Section: Applications In Biomedical Research In Vivo Tumor Imagingmentioning

confidence: 82%

Section: Recent Advances In Cerenkov Luminescence Imaging (Cli)mentioning

confidence: 99%

Section: Cross Validations Of CLI Petmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Xu¹,

Liu²,

Cheng³

2011

J Nucl Med

129

178

View full text Add to dashboard Cite

show abstract

“…CLI is emerging as a promising molecular imaging technique that has found potentials in many basic science research applications and even clinical use 4,5,15,16,17 . The major advantages of CLI over traditional nuclear imaging modalities such as PET stem from its use of OI instruments, which are easier to use, characterized by short acquisition time and high throughput, significantly less expensive, and more widely available to researchers.…”

Section: Discussionmentioning

confidence: 99%

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Liu

Chang

et al. 2012

JoVE

View full text Add to dashboard Cite

In molecular imaging, positron emission tomography (PET) and optical imaging (OI) are two of the most important and thus most widely used modalities [1][2][3] . PET is characterized by its excellent sensitivity and quantification ability while OI is notable for non-radiation, relative low cost, short scanning time, high throughput, and wide availability to basic researchers. However, both modalities have their shortcomings as well. PET suffers from poor spatial resolution and high cost, while OI is mostly limited to preclinical applications because of its limited tissue penetration along with prominent scattering optical signals through the thickness of living tissues.Recently a bridge between PET and OI has emerged with the discovery of Cerenkov Luminescence Imaging (CLI) [4][5][6] . CLI is a new imaging modality that harnesses Cerenkov Radiation (CR) to image radionuclides with OI instruments. Russian Nobel laureate Alekseyevich Cerenkov and his colleagues originally discovered CR in 1934. It is a form of electromagnetic radiation emitted when a charged particle travels at a superluminal speed in a dielectric medium 7,8 . The charged particle, whether positron or electron, perturbs the electromagnetic field of the medium by displacing the electrons in its atoms. After passing of the disruption photons are emitted as the displaced electrons return to the ground state. For instance, one Since its emergence, CLI has been investigated for its use in a variety of preclinical applications including in vivo tumor imaging, reporter gene imaging, radiotracer development, multimodality imaging, among others 4,5,9,10,11 . The most important reason why CLI has enjoyed much success so far is that this new technology takes advantage of the low cost and wide availability of OI to image radionuclides, which used to be imaged only by more expensive and less available nuclear imaging modalities such as PET.Here, we present the method of using CLI to monitor cancer drug therapy. Our group has recently investigated this new application and validated its feasibility by a proof-of-concept study 12 . We demonstrated that CLI and PET exhibited excellent correlations across different tumor xenografts and imaging probes. This is consistent with the overarching principle of CR that CLI essentially visualizes the same radionuclides as PET. We selected Bevacizumab (Avastin; Genentech/Roche) as our therapeutic agent because it is a well-known angiogenesis inhibitor 13,14 . Maturation of this technology in the near future can be envisioned to have a significant impact on preclinical drug development, screening, as well as therapy monitoring of patients receiving treatments. Video LinkThe video component of this article can be found at http://www.jove.com/video/4341/ Protocol 1. Tumor Model 1. Culture H460 cells (American Type Culture Collection) in RPMI 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin (Invitrogen Life Technologies). It should be noted that the choices of cell lines, culture medium...

show abstract

“…However, as long as positron emitters are applied, positron escape from the sample will always remain an issue when they are used with plant samples. Recently, an optical imaging method using Cerenkov radiation from radioisotopes has been reported [7]. In order to obtain luminescent signal for imaging, the Cerenkov energy passing through the water in the sample should be higher than 262 keV, which limits the kinds of applicable isotopes.…”

Section: Introductionmentioning

confidence: 99%

Development of real-time radioisotope imaging systems for plant nutrient uptake studies

Kanno

Yamawaki

Ishibashi

et al. 2012

Phil. Trans. R. Soc. B

View full text Add to dashboard Cite

Ionic nutrition is essential for plant development. Many techniques have been developed to image and (or) measure ionic movement in plants. Nevertheless, most of them are destructive and limit the analysis. Here, we present the development of radioisotope imaging techniques that overcome such restrictions and allow for real-time imaging of ionic movement. The first system, called macroimaging, was developed to visualize and measure ion uptake and translocation between organs at a whole-plant scale. Such a device is fully compatible with illumination of the sample. We also modified fluorescent microscopes to set up various solutions for ion uptake analysis at the microscopic level. Both systems allow numerical analysis of images and possess a wide dynamic range of detection because they are based on radioactivity.

show abstract

Luminescence imaging using radionuclides: a potential application in molecular imaging

Cited by 49 publications

References 18 publications

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Harnessing the Power of Radionuclides for Optical Imaging: Cerenkov Luminescence Imaging

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Development of real-time radioisotope imaging systems for plant nutrient uptake studies

Contact Info

Product

Resources

About